List view / Grid view
14 June 2016 | By Victoria White, Digital Content Producer
Two studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints...
14 June 2016 | By Victoria White, Digital Content Producer
Merck has announced results from two Phase III studies evaluating MK-1293 for the treatment of people with type 1 and type 2 diabetes...
13 June 2016 | By Victoria White, Digital Content Producer
New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes...
Results from Sanofi’s Phase III LixiLan-O and LixiLan-L clinical trials have been presented at the American Diabetes Association 76th Scientific Sessions.
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
13 June 2016 | By Victoria White, Digital Content Producer
Novo Nordisk presented new findings from separate studies of Tresiba and semaglutide at the American Diabetes Association 76th Scientific Sessions...
26 May 2016 | By Victoria White, Digital Content Producer
The FDA's EMDAC has recommended the approval of the NDA for the fixed-ratio combination of insulin glargine and lixisenatide...
25 May 2016 | By Victoria White, Digital Content Producer
NICE has published final guidance recommending three drugs for treating type 2 diabetes: canagliflozin, dapagliflozin and empagliflozin...
Stem cell therapy is currently utilised in medicine for its application in tissue repair and regenerative medicine. Unique characteristics of stem cells, such as self-renewal and differentiation, allow its function to be applicable for therapeutic purposes. Nanotechnology and cell microencapsulation have been researched and used as a means to protect…
For diabetes mellitus patients who treat themselves with insulin, the need to self-monitor blood glucose in order to establish their insulin dose is a major burden, and highlights the need to develop non-invasive glucose measurement technologies. Up until now, such non-invasive systems that also have adequate measurement performance under daily…
28 April 2016 | By Victoria White, Digital Content Producer
Adocia and Lilly have announced positive topline results from a Phase Ib trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro...
12 April 2016 | By Victoria White, Digital Content Producer
HinsBet is a rapid-acting formulation of recombinant human insulin using BioChaperone, which is designed to accelerate insulin absorption...
5 April 2016 | By Victoria White
In a three year trial, individuals treated with Saxenda lost more weight (6.1%) than those treated with placebo (1.9%)...
2 April 2016 | By Victoria White
Semaglutide significantly improved glycaemic control compared to placebo in adults with type 2 diabetes previously managed with diet and exercise alone...
4 March 2016 | By Victoria White
Victoza (liraglutide) was studied over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events...
